Oxatera® (Oxatera®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceOxaliplatinOxaliplatin
Similar drugsTo uncover
  • GESSEDYL
    lyophilizate d / infusion 
    Egis Pharmaceutical Plant OJSC     Hungary
  • Oxaliplatin
    concentrate d / infusion 
    JODAS EKSPOIM, LLC     Russia
  • Oxaliplatin
    lyophilizate d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Oxaliplatinum medec
    lyophilizate d / infusion 
    medac GmbH     Germany
  • Oxaliplatin-RONTS®
    concentrate d / infusion 
    RNTS named after N.N. Blokhin RAMS     Russia
  • Oxaliplatin-Teva
    concentrate d / infusion 
    Teva Pharmaceutical Enterprises Co., Ltd.     Israel
  • Oxaliplatin-Phylaxis
    lyophilizate d / infusion 
    CEFARMA, LLC     Russia
  • Oxaliplatin-Ebwe
    lyophilizate d / infusion 
    Ebewe Pharma Gesmb.b. Nfg. KG     Austria
  • Oxatera®
    lyophilizate d / infusion 
    Laboratory Tutor SAASIFAA     Argentina
  • Oxatera®
    lyophilizate d / infusion 
    Laboratory Tutor SAASIFAA     Argentina
  • Оксиплат
    lyophilizate d / infusion 
    San Pharmaceutical Industries Co., Ltd.     India
  • Oxitane
    concentrate d / infusion 
    Fresenius Kabi Deutschland GmbH     Germany
  • Plaksat
    lyophilizate d / infusion 
    Actavis PTS ehf Group     Iceland
  • Platikad
    lyophilizate d / infusion 
    BIOCAD, CJSC     Russia
  • Platikad®
    lyophilizate d / infusion 
    BIOCAD, CJSC     Russia
  • Texalko
    lyophilizate d / infusion 
    GlaxoSmithKline Trading, ZAO     Russia
  • Flatyboard
    concentrate d / infusion 
    Pharmaceuticals Nord, JSC     Russia
  • The Exorcum
    lyophilizate d / infusion 
    LENS-PHARM, LLC     Russia
  • The Exorcum
    lyophilizate d / infusion 
    LENS-PHARM, LLC     Russia
  • Eloxatin®
    concentrate d / infusion 
    Sanofi-Aventis France     France
    • Dosage form: & nbsplyophilizate for solution for infusion
    Pharmacotherapeutic group:An antitumour agent, an alkylating compound
    ATX: & nbsp

    L.01.X.A   Platinum compounds

    L.01.X.A.03   Oxaliplatin

    Form release / dosage:Lyophilizate for the preparation of a solution for infusions, 150 mg.
    Packaging:For 150 mg of oxaliplatin in bottles of brown glass USP type I, ukuporennyh brombutilovoy rubber stopper and crimped aluminum cap with a plastic cover Flip Off. For 1 bottle of the drug with instructions for use in a cardboard bundle.
    For 150 mg of oxaliplatin in bottles of brown glass USP type I, ukuporennyh brombutilovoy rubber stopper and crimped aluminum cap with a plastic cover Flip Off. 144 bottles of 150 mg of the drug in individual cardboard packs without labeling are placed in a cardboard box.
    Storage conditions: At a temperature of 15 to 25 FROM in a dry place protected from light.
    Keep out of the reach of children.
    Shelf life:3 years.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001567
    Date of registration:06.03.2012
    Expiration Date:06.03.2017
    The owner of the registration certificate:Laboratory Tutor SAASIFAALaboratory Tutor SAASIFAA Argentina
    Manufacturer: & nbsp
    Information update date: & nbsp23.05.2017
    Illustrated instructions
      Instructions
      Up